A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

NCT07185776 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

203

Enrollment

INDUSTRY

Sponsor class

Conditions

Lipoprotein Disorder

Interventions

DRUG: HRS-5632 Injection
DRUG: HRS-5632 Injection Placebo

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.